Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)

NCT02193360 is registered in ClinicalTrials.gov with Fast Forward Pharmaceuticals as lead sponsor.

NCT NCT02193360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02193360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)
Lead sponsor
Fast Forward Pharmaceuticals
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2015
Completion date
December 31, 2017
Enrollment
24 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cirrhosis